Sao Tome and Principe
Tuberculosis profile
Population  2012 <1 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.03 (0.012–0.055) 16 (6.4–29)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 3 (2.4–3.8)
Prevalence  (includes HIV+TB) 0.3 (0.15–0.5) 159 (80–264)
Incidence  (includes HIV+TB) 0.17 (0.14–0.21) 93 (76–111)
Incidence (HIV+TB only) 0.017 (0.014–0.021) 9.2 (7.5–11)
Case detection, all forms (%) 66 (55–80)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 59 (53) Relapse 3 (20)
Smear-negative 34 (30) Treatment after failure 8 (53)
Smear-unknown / not done 3 (3) Treatment after default 3 (20)
Extrapulmonary 16 (14) Other 1 (7)
Other 0 (0)      
Total new 112   Total retreatment 15  
           
Other (history unknown) 0        
Total new and relapse 115   Total cases notified 127  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 1.6 1.5 1.3
Age < 15 1 8 6
Laboratories 2012
Smear (per 100 000 population) 4.3
Culture (per 5 million population) 0
Drug susceptibility testing (per 5 million population) 0
Is second-line drug susceptibility testing available? No
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 72   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 65  
Retreatment 31  
TB/HIV 2012 Number (%)
TB patients with known HIV status 126 (99)
HIV-positive TB patients 18 (14)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 18 (100)
HIV-positive TB patients on antiretroviral therapy (ART) 18 (100)
HIV-positive people screened for TB    
HIV-positive people provided with IPT 0  
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 1.8 (0.1–3.4) 88 (47–100)
MDR-TB cases among notified pulmonary
TB cases
2 (0–3) 13 (7–15)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 16 (27%) 8 (53%) 24
Laboratory-confirmed MDR-TB cases 1 7 8
Patients started on MDR-TB treatment     8
Financing TB control 2013
National TB programme budget (US$ millions) 2
% Funded domestically <1%
% Funded internationally 46%
% Unfunded 53%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-24 Data: www.who.int/tb/data